Regeneron (REGN) Pharmaceuticals’ treatment of pulmonary arterial hypertension was granted FDA orphan designation status, according to a post to the agency’s website.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Sanofi, Regeneron report all primary endpoints met in LIBERTY-AFRS-AIMS study
- Regeneron, Sanofi announces presentation of Phase 3 trial of Dupixent
- Regeneron price target raised to $660 from $595 at UBS
- Regeneron’s Aflibercept Study Completion: Implications for Investors
- Insider Moves: Blackstone, Regeneron, Schwab, Celestica, Corning